Thermo Fisher earnings increased in the third quarter of 2026 as stronger pharmaceutical services activity and instrument demand helped revenue grow 9% to $12.14 billion. On October 21, the company reported adjusted earnings per share of $6.68, up 15%, and raised its full-year revenue, adjusted earnings and free-cash-flow guidance.
Key Takeaways
- Organic revenue grew 6%, while adjusted operating margin increased to 24.5%.
- Tariff refunds supported profit, and some pharmaceutical services activity shifted into the third quarter.
- Management raised its 2026 outlook but maintained a slower fourth-quarter organic growth forecast of 4%.
Table of Contents
- Thermo Fisher earnings grow faster than revenue
- Pharma services lead an uneven recovery
- Higher annual guidance still implies a slower fourth quarter
- Cash generation supports planned capital returns
- Conclusion
Thermo Fisher earnings grow faster than revenue
The company’s third-quarter results announcement covers the three months ended September 26, 2026. Revenue increased from $11.12 billion a year earlier, with acquisitions contributing four percentage points to growth and the microbiology divestiture subtracting one point. Organic growth, which excludes acquisition, divestiture and currency effects, was 6%.
Adjusted operating income rose 15% to $2.97 billion, and adjusted operating margin expanded by 120 basis points to 24.5%. Management cited productivity and the benefit of higher sales volumes. Tariff refunds also provided a roughly $60 million net benefit to adjusted operating income, equivalent to 50 basis points of margin and $0.15 per share.
GAAP diluted earnings per share rose 9% to $4.64, while GAAP operating income increased 17% to $2.26 billion. The distinction matters: adjusted earnings exclude items such as acquisition-related intangible amortization and restructuring costs, so the $6.68 adjusted figure is not the company’s reported GAAP profit per share.
| Item | Details |
|---|---|
| Life Sciences Solutions | Q3 reported revenue growth: 5%; organic growth: 1%; adjusted operating margin: 37.6%. |
| Analytical Instruments | Q3 reported revenue growth: 6%; organic growth: 6%; adjusted operating margin: 26.9%. |
| Specialty Diagnostics | Q3 reported revenue growth: -6%; organic growth: flat; adjusted operating margin: 31.0%. |
| Laboratory Products and Biopharma Services | Q3 reported revenue growth: 15%; organic growth: 10%; adjusted operating margin: 15.5%. |
Pharma services lead an uneven recovery
Laboratory Products and Biopharma Services delivered the strongest segment growth. Chief Financial Officer Jim Meyer said pharmaceutical services activity accelerated meaningfully in the second half, with some customer work completed in the third quarter rather than the fourth.
Chief Executive Officer Marc Casper described broader improvement across customer markets. Pharmaceutical and biotechnology revenue grew at a high-single-digit rate, as did industrial and applied markets. Semiconductor-related electron microscopy was a particular area of strength, while China revenue increased at a low-double-digit rate.
The recovery was not uniform. Academic and government revenue was flat, and demand for bioscience and genetic science reagents remained muted. Casper said clinical research activity had recovered before laboratory research spending, helping explain why Life Sciences Solutions lagged the faster-growing services business.
Higher annual guidance still implies a slower fourth quarter
During the earnings call, management raised its 2026 revenue forecast to $47.7 billion–$48.2 billion, representing reported growth of 7%–8% and organic growth of 4%. Adjusted EPS guidance increased to $25.13–$25.43, or growth of 10%–11%.
The company raised its second-half organic growth outlook to 5% from 4%, but maintained a fourth-quarter forecast of 4%. Meyer attributed the difference from the third quarter’s 6% growth partly to the timing of pharmaceutical services work. The annual upgrade therefore should not be read as a forecast that the third-quarter growth rate will persist.
Casper declined to provide 2027 guidance before the February 2 earnings call. He reiterated that 7% organic growth remained a reasonable normal growth outlook, rather than a current annual forecast.
Cash generation supports planned capital returns
Through September 26, operating cash flow totaled $5.87 billion and free cash flow reached $4.62 billion. Management raised its full-year free-cash-flow outlook to $7.0 billion–$7.5 billion and expects net capital expenditure of $1.9 billion–$2.0 billion.
The annual outlook assumes $4 billion in share repurchases and approximately $700 million in dividends. These are full-year planning figures, not amounts established as already distributed. At quarter-end, Thermo Fisher held $6.1 billion in cash and short-term investments against total debt of $41.4 billion.
Conclusion
Thermo Fisher’s stronger quarter supported higher annual targets, although tariff refunds and customer timing contributed to the results. The next operating checkpoint is management’s 4% fourth-quarter organic growth forecast, followed by the 2027 outlook planned for the February 2 earnings call.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
